+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton pump inhibitors do not increase the risk of acute rejection

Proton pump inhibitors do not increase the risk of acute rejection

Netherlands Journal of Medicine 72(2): 86-90

Mycophenolate mofetil (MMF) is the prodrug of mycophenolic acid (MPA). Proton pump inhibitors impair exposure to MPA due to incomplete conversion from MMF. Lower exposure to MPA could result in an increased risk of acute rejection. We investigated whether MMF-treated renal transplant patients who concomitantly used pantoprazole as ulcer prophylaxis had a higher risk of acute rejection within the first three months after transplantation than those who used ranitidine. We performed a retrospective study in adult patients who underwent kidney transplantation between January 2007 and December 2011. Their immunosuppressive therapy consisted of steroids, tacrolimus and MMF and they used either pantoprazole or ranitidine as ulcer prophylaxis. 202 patients were included: 125 using pantoprazole and 77 using ranitidine. There was no difference in the number of patients with biopsy-proven acute rejection (BPAR): 13 (10.4%) in the pantoprazole group versus 7 (9.1%) in the ranitidine group (NS). Also after correction for inequalities between the two groups, there was no significant relationship between the risk of BPAR and the type of anti-ulcer agent. There was no evidence for an increased incidence of BPAR in renal transplant patients who use pantoprazole in combination with MMF.

(PDF emailed within 1 workday: $29.90)

Accession: 055260354

Download citation: RISBibTeXText

PMID: 24659591

Related references

Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI. Evidence-Based Medicine 14(5): 154-154, 2009

ACP Journal Club. Concomitant use of proton pump inhibitors with clopidogrel may increase risk for readmission after discharge for acute MI. Annals of Internal Medicine 151(4): Jc2-J13, 2009

No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014). Gastroenterology, 2017

Do Proton Pump Inhibitors Increase the Risk of Dementia?. JAMA Neurology 73(4): 379-381, 2016

Do proton pump inhibitors increase the risk of myocardial infarction?. Gastroenterologia Y Hepatologia 39(6): 365-368, 2016

Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation 97(5): 518-524, 2014

Do opioids, sedatives and proton-pump inhibitors increase the risk of fractures?. Laeknabladid 103(5): 231-235, 2017

Long term use of proton pump inhibitors may increase risk of impaired kidney function. Bmj 353: I2163-I2163, 2016

Proton Pump Inhibitors Increase The Overall Risk Of Developing Bacterial Infections In Patients With Cirrhosis. Arquivos de Gastroenterologia 55(1): 28-32, 2018

Proton pump inhibitors and fracture: they impair bone quality and increase fall risk?. Osteoporosis International 27(4): 1675-1676, 2016

Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists. PharmacoTherapy, 2017

Proton pump inhibitors increase the risk of cholecystitis: a population-based case-control study. Gut, 2018

Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in Population Study. Gastroenterology (): -, 2016

Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis. Journal of Gastroenterology and Hepatology 32(5): 1064-1070, 2017

Proton Pump Inhibitors Did Not Increase Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease. Journal of Clinical Medicine Research 7(11): 880-883, 2015